-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compared with aspirin (ASA) monotherapy, dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel (ASA+CLO) reduces the risk of early recurrent stroke after minor ischemic stroke or high-risk TIA, but the first The effect of DAPT on stroke risk reduction gradually diminished after one month, and from then on also increased the risk of major bleeding (vs ASA)
stroke
Another DAPT is a dual antiplatelet strategy based on cilostazol (CLZ).
In March 2022, Kazunori Toyoda et al.
In March 2022, Kazunori Toyoda et al.
Of the 1879 patients, 498 belonged to the 8-14 day group, 467 belonged to the 15-28 day group, and 914 belonged to the 29-180 day group
For recurrent ischemic stroke, there was a significant treatment-by-subgroup interaction between the trial treatment groups and the three groups
The authors concluded that a long-term DAPT (cilostazol-containing) strategy initiated 15-180 days after stroke was more effective in secondary stroke prevention than DAPT (cilostazol-containing) initiated 8-14 days after stroke ( vs single agent) and did not increase the risk of bleeding
A long-term DAPT (with cilostazol) strategy initiated 15-180 days after onset was more effective in secondary stroke prevention compared with initiation of DAPT (with cilostazol) 8-14 days after stroke (vs single agent) , and did not increase the risk of bleeding prophylaxis
Original source:
Original source:Kazunori Toyoda, Katsuhiro Omae, Haruhiko Hoshino, et al.
Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.
com Trial Post Hoc Analysis.
Leave a Comment here
